Enanta Pharmaceuticals (ENTA) Proxy Filing summary

Executive summary

• Annual meeting scheduled for March 11, 2026, to be held virtually for shareholders of record as of January 16, 2026.

• Proxy materials, including the notice, proxy statement, and annual report, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of two Class I directors to serve until the 2029 annual meeting or until successors are qualified.

• Approval of an amendment to the 2019 Equity Incentive Plan.

• Advisory vote on executive compensation for named executive officers.

• Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026.

• Board recommends voting for all director nominees and all proposals.

Board of directors and corporate governance

• Board recommends the election of Bruce L.A. Carter, Ph.D., and Jay R. Luly, Ph.D., as Class I directors.